MX2018003893A - Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. - Google Patents
Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.Info
- Publication number
- MX2018003893A MX2018003893A MX2018003893A MX2018003893A MX2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A
- Authority
- MX
- Mexico
- Prior art keywords
- diaminopirimidine
- receptor modulators
- treatment
- cough
- tos
- Prior art date
Links
- 102100040460 P2X purinoceptor 3 Human genes 0.000 title abstract 2
- 101710189970 P2X purinoceptor 3 Proteins 0.000 title abstract 2
- 102100040479 P2X purinoceptor 2 Human genes 0.000 title 1
- 101710189968 P2X purinoceptor 2 Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 206010011224 Cough Diseases 0.000 abstract 3
- TZHOVNUCGUXMCS-UHFFFAOYSA-N 5-(2-ethynyl-5-propan-2-ylpyridin-4-yl)oxypyrimidine-2,4-diamine Chemical compound C(#C)C1=NC=C(C(=C1)OC=1C(=NC(=NC=1)N)N)C(C)C TZHOVNUCGUXMCS-UHFFFAOYSA-N 0.000 abstract 1
- 208000013116 chronic cough Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Metodos de tratamiento de la tos, tos cronica y deseo de toser asociados con enfermedades respiratorias, con un antagonista del receptor P2X3 y/o P2X2/3, los métodos comprendiendo administrarle a un sujeto que lo necesite una cantidad eficaz de 5 un compuesto de la formula (I): ver fórmula (I), o una sal farmaceuticamente aceptable del mismo, en donde R1 y R2 son como se define en la presente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234584P | 2015-09-29 | 2015-09-29 | |
| US201662336381P | 2016-05-13 | 2016-05-13 | |
| PCT/US2016/053223 WO2017058645A1 (en) | 2015-09-29 | 2016-09-23 | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018003893A true MX2018003893A (es) | 2018-06-22 |
| MX390084B MX390084B (es) | 2025-03-20 |
Family
ID=58424436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003893A MX390084B (es) | 2015-09-29 | 2016-09-23 | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11260056B2 (es) |
| EP (2) | EP3355889B1 (es) |
| JP (1) | JP6877441B2 (es) |
| KR (1) | KR20180054843A (es) |
| AU (1) | AU2016330466B2 (es) |
| CA (1) | CA2998742C (es) |
| CY (2) | CY1125963T1 (es) |
| DK (1) | DK3355889T3 (es) |
| ES (1) | ES2942711T3 (es) |
| FI (2) | FI3355889T3 (es) |
| FR (1) | FR24C1010I2 (es) |
| HR (1) | HRP20230445T1 (es) |
| HU (2) | HUE061764T2 (es) |
| LT (2) | LT3355889T (es) |
| MX (1) | MX390084B (es) |
| NL (1) | NL301260I2 (es) |
| NO (1) | NO2024009I1 (es) |
| PL (1) | PL3355889T3 (es) |
| PT (1) | PT3355889T (es) |
| RS (1) | RS64155B1 (es) |
| SI (1) | SI3355889T1 (es) |
| WO (1) | WO2017058645A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6934945B2 (ja) | 2016-12-20 | 2021-09-15 | アファレント ファーマシューティカルズ インコーポレイテッド | Ｐ２ｘ３アンタゴニストの結晶塩および多形 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| KR20210009341A (ko) * | 2018-05-15 | 2021-01-26 | 바이엘 악티엔게젤샤프트 | 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드 |
| WO2020071530A1 (ja) | 2018-10-05 | 2020-04-09 | 塩野義製薬株式会社 | 慢性咳嗽治療用医薬 |
| CN113727716A (zh) | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | 采用p2x3调节剂的治疗 |
| US20220211703A1 (en) * | 2019-04-30 | 2022-07-07 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| WO2020239953A1 (en) | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Pyridopyrimidines derivatives as p2x3 inhibitors |
| GEP20257823B (en) | 2019-05-31 | 2025-11-10 | Chiesi Farm Spa | Amino quinazoline derivatives as p2x3 inhibitors |
| KR20220066307A (ko) | 2019-09-19 | 2022-05-24 | 시오노기 앤드 컴파니, 리미티드 | 1,3,5-트라이아진 유도체 또는 그의 용매화물의 결정 및 그 제조 방법 |
| CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
| AU2021386684A1 (en) | 2020-11-27 | 2023-05-25 | Chiesi Farmaceutici S.P.A. | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| CN116601149A (zh) | 2020-11-27 | 2023-08-15 | 奇斯药制品公司 | 作为p2x3抑制剂的氨基喹唑啉衍生物 |
| KR20230113289A (ko) | 2020-11-27 | 2023-07-28 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 프탈라진 유도체 |
| CN116396285A (zh) * | 2022-01-04 | 2023-07-07 | 上海华汇拓医药科技有限公司 | 氘代四氢呋喃类化合物制备及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2391636T3 (es) | 2004-03-05 | 2012-11-28 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como antagonistas de P2X3 y P2X2/3 |
| CA2573565A1 (en) | 2004-07-22 | 2006-02-02 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
| CA2620129C (en) | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| ATE529413T1 (de) | 2005-09-01 | 2011-11-15 | Hoffmann La Roche | Verfahren zur synthese von aryloxydiaminopyrimidinen |
| EP1924564B1 (en) | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP1924264B9 (en) * | 2005-09-01 | 2014-02-19 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| ES2461595T3 (es) | 2006-10-04 | 2014-05-20 | F. Hoffmann-La Roche Ag | Proceso para la síntesis de derivados de fenoxi-diaminopirimidina |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| SG11201601145RA (en) | 2013-08-23 | 2016-03-30 | Afferent Pharmaceuticals Inc | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
-
2016
- 2016-09-23 EP EP16852340.5A patent/EP3355889B1/en active Active
- 2016-09-23 CA CA2998742A patent/CA2998742C/en active Active
- 2016-09-23 MX MX2018003893A patent/MX390084B/es unknown
- 2016-09-23 SI SI201631686T patent/SI3355889T1/sl unknown
- 2016-09-23 PT PT168523405T patent/PT3355889T/pt unknown
- 2016-09-23 HU HUE16852340A patent/HUE061764T2/hu unknown
- 2016-09-23 DK DK16852340.5T patent/DK3355889T3/da active
- 2016-09-23 KR KR1020187011747A patent/KR20180054843A/ko not_active Ceased
- 2016-09-23 HR HRP20230445TT patent/HRP20230445T1/hr unknown
- 2016-09-23 LT LTEPPCT/US2016/053223T patent/LT3355889T/lt unknown
- 2016-09-23 US US15/764,174 patent/US11260056B2/en active Active
- 2016-09-23 AU AU2016330466A patent/AU2016330466B2/en active Active
- 2016-09-23 WO PCT/US2016/053223 patent/WO2017058645A1/en not_active Ceased
- 2016-09-23 PL PL16852340.5T patent/PL3355889T3/pl unknown
- 2016-09-23 ES ES16852340T patent/ES2942711T3/es active Active
- 2016-09-23 RS RS20230321A patent/RS64155B1/sr unknown
- 2016-09-23 JP JP2018535821A patent/JP6877441B2/ja active Active
- 2016-09-23 EP EP23155536.8A patent/EP4215182A1/en active Pending
- 2016-09-23 FI FIEP16852340.5T patent/FI3355889T3/fi active
-
2022
- 2022-01-24 US US17/582,485 patent/US20220143015A1/en not_active Abandoned
-
2023
- 2023-05-09 CY CY20231100217T patent/CY1125963T1/el unknown
-
2024
- 2024-03-04 NL NL301260C patent/NL301260I2/nl unknown
- 2024-03-05 HU HUS2400004C patent/HUS2400004I1/hu unknown
- 2024-03-06 NO NO2024009C patent/NO2024009I1/no unknown
- 2024-03-12 LT LTPA2024507C patent/LTPA2024507I1/lt unknown
- 2024-03-12 FR FR24C1010C patent/FR24C1010I2/fr active Active
- 2024-03-13 CY CY2024005C patent/CY2024005I1/el unknown
- 2024-03-13 FI FIC20240006C patent/FIC20240006I1/fi unknown
- 2024-04-19 US US18/640,100 patent/US20240285620A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| CR20160093A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| GT201700146A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| MX391858B (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| MX2016010328A (es) | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX2019003710A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX377172B (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| MX2017012926A (es) | Inhibidores y sus usos. | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios |